AIM ImmunoTech arrives at its May 22 earnings event in the wake of one of the most severe drawdowns among micro-cap biotechs this year — down 56% in a single month, with the stock at $0.25.
The price collapse is the most striking fact about the setup. The stock lost a quarter of its value in just the past week. That crash followed the prior print on March 27, where AIM shed more than 20% in a single session and finished 14.6% lower over the subsequent five days. The market's reaction to the last report was severe. The upcoming release arrives against a backdrop where sentiment has not recovered.
Short interest tells a nuanced story. At 7.7% of free float, bears hold a meaningful position — but the borrow market has undergone a dramatic shift in the past ten days. Through early May, availability was extremely tight, running below 50% of estimated short interest and borrowing costs were running above 250% annualised. Since May 12, availability has snapped back sharply to 642%, meaning borrow supply has vastly outpaced current short positions. Cost to borrow has eased to 159% — still very high, but down from a recent peak above 340% in early April. The short score has also dropped from 67 to 51 over the past week, reflecting a partial unwind of bearish positioning rather than a fresh build. Short sellers appear to be reducing exposure into the event, not adding to it.
The debate around AIM centres on whether Ampligen — its flagship immunotherapy — can generate enough clinical momentum to justify continued funding. Bulls point to Phase 2 data in colorectal cancer and post-COVID indications as genuine catalysts, and the EPS surprise factor scores in the 91st percentile, suggesting the company has a history of beating its own estimates. Bears point to a $3 million quarterly net loss on just $22,000 in revenue, a current ratio barely above 1.0, and a stock that has absorbed a string of analyst target cuts — Ascendiant's Edward Woo lowered his target from $22 to $10 in April, having already slashed it from $150 to $24 the prior October. The single analyst covering the stock maintains a Buy, but the target gap between $10 and a $0.25 market price suggests institutional confidence is almost entirely forward-looking and conditional on clinical outcomes. Given the data-consistency gap between that target and the current price, that figure is best treated as a scenario price rather than a near-term expectation.
Ownership concentration adds one further dimension. Orca Capital GmbH disclosed a 22% stake as of early May — a position initiated entirely in the most recent filing period. For a company with a sub-$2.5 million market cap and a quick ratio below 1, a single large new shareholder of that scale could become significant to the liquidity picture depending on its intentions.
The May 22 print is therefore less a test of whether AIM can beat earnings — it has historically managed that — and more a test of whether the Ampligen pipeline carries enough clinical specificity to stabilise the stock after two consecutive quarters of double-digit post-earnings declines.
See the live data behind this article on ORTEX.
Open AIM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
